From: A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain
First author, publication year | Country | Features of RCT | Sample size (M; F) | Mean age | Route | Comparator drugs | Outcome measurement | Remarks |
---|---|---|---|---|---|---|---|---|
Aurilio 2009 | Italy | Cross-over | 32 (7:15) | 62 (42-78) | TD | TD fentanyl | VAS, PPI, PRI | ITT |
Bohme 2003 | Austria, Germany, Hungary | Multicenter | 151 (70:81) | 60.6 (± 12.2) | TD | Placebo | VRS, responder | Complete enriched; mixed with non-cancer & cancer patients |
Bono 1997 | Italy | Cross-over | 60 (44:16) | 61.4 (40-84) | SL | Oral tramadol | VAS, KSI | Non-English |
Brema 1996 | Italy | Multicenter | 131 (86:45) | SL | Oral tramadol | VAS, KSI | Non-English | |
De Conno 1987 | Italy | Cross-over | 91 | SL | Oral pentazocine | Pain relief, KSI | Non-English | |
Dini 1986 | Italy | Single centre | 42 (21;21) | 0.3 mg | SL & IM | Oral pentazocine & IM pentazocine | Pain reduction. PI | Non-English |
Kjaer 1982 | Denmark | Single centre | 27 (13:14) | 60 (41-71) | IM | IM morphine | Pain reduction | |
Likar 2007 | Austria | Cross-over, open label | 17 | 61.6 (±11.5) | TD | TD buprenorphine (4day vs 3 day regimen) | PI | A subset of cancer patients |
Noda 1989 | Japan | Single centre | 30 | range: 25-72 | SC & IM | Placebo | VAS | |
Pace 2007 | Italy | Open label | 52 (27:15) | 55 (± 2.6) | TD | Morphine | PI | Non-enriched |
Poulain 2008 | Multicenter | 189 | 63 (33-83) | TD | Placebo | PI | Enriched; calculated sample size | |
Sittl 2003 | Austria, Germany, Netherland | Multicenter, multidose | 157 (71:86) | 58.7 (±11.8) | TD | Placebo | Pain relief, PI, satisfaction | 3 dosage of TD |
Sorge 2004 | Germany, Poland | Multicenter, multidose | 137 | 56 (±12.1) | TD | Placebo | VRS, | Complete enriched; 33% cancer patients |
Taguchi 1982 | Japan | Cross-over | 31 | IM | IM pentazocine | PI | Non- English | |
Ventafridda 1983 | Italy | Cross-over | 60 (42:18) | >18 | SL | Oral pentazocine | VAS, PI | VAS |
Wirz 2009 | Germany | Multidrug | 174 (98:76) | 65.3 (±10.7) | TD | Oral hydromorphone | PI, rescue | Prospective |